Summary: This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4) conjugated via a AcBut linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Calicheamicin binds to DNA, causes DNA damage. http://www.creative-biolabs.com/adc/target-cd22-10.htm